清远招聘

Report to: Senior Medical Manager

Position Overview & Key Results Areas

The Medical Science Liaison serves as an advocate for company science within the healthcare community. By virtue of his/her training, the MSL is well-positioned to discuss and provide scientific and therapeutic information to Health Care Professionals and Researchers (Clinical and Scientific Leaders) viewed by their peers to be authorities in a therapeutic field. The MSL is responsible for ensuring that he/she is fully versed in the therapeutic area and up-to-date on all major studies, both ongoing and completed, competitive product information and clinical data.

Engagements with External Experts

Develop an understanding of regional and national scientific leaders and the healthcare environments in which they work through effective professional engagement with scientific leaders that are centered on science and credible exchange of unbiased scientific information.

?Interact with managed care organizations, healthcare professionals, clinical investigators, and other healthcare organizations providing fair, balanced, and scientifically rigorous medical and clinical information.

?Meet with healthcare professionals who might be interested in engaging in a scientific discussion regarding a product’s medical and clinical profile in the context of approved prescribing information as well as in response to unsolicited questions or requests for information which may involve off-label information. (Unsolicited means that the information request was neither suggested nor encouraged by the MSL or sales representatives)

? Participate in the development and implement tactics identified in the Medical Affairs Plans (MAP).

?Work with clinical research personnel to identify potential investigators clinical research projects, based on the investigator's expertise and access to appropriate patients.

?Alert investigators to company program for Investigator Initiated Study Proposals, working together with the medical manager on the process for submitting investigator designed proposals for review and approval; encourage and facilitate research publication of investigator initiated studies, in strict compliance with company policy and local country regulations.

?When requested (and consistent with local SOPs), may represent the Medical Department at Local or Regional Medical events (e.g. Medical Congresses and Symposia.)

? Facilitate the submission and publication of the study result from investigator initiated or company initiated projects.

Background requirements

?Candidates to possess a master degree in the life sciences (MD, Pharm.D, or Pharmacist, Biology) preferably with a specialization in the experience of Oncology.

?Requires strong scientific baseline knowledge in therapeutic area, clinical trials methods, implementation and interpretation, sound scientific and clinical judgment, and eagerness to learn more in depth in therapeutic area.

? Strong, confident and engaging presentation skill, and capable for customer facing.

? Outstanding communication and skills and the ability to function within a team environment.

? Proactive

和黄中国医药科技有限公司（简称“ 和黄医药 ”或“ Chi-Med ”）（纳斯达克 / 伦交所：HCM）是一家创新型生物医药公司，在过去20年间致力于发现和全球开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。目前，和黄医药共有8个抗癌类候选药物正在全球开发中，并在中国本土市场拥有广泛的商业网络。

和黄医药成立于2002年，为在纽约和伦敦两地上市的和黄中国医药科技有限公司（纳斯达克/伦交所： HCM）旗下专注于新药研发业务的子公司, 研发中心坐落在上海浦东张江高科技园区，海外临床开发及注册中心位于美国新泽西，具有完备的研发平台和GMP生产基地。管理团队成员均有在知名跨国医药和生物医药企业工作的经历，参与了多个全球新药研发；公司目前有500余位来自海内外，拥有丰富新药研发经验的科研人员，8大临床在研药物、 30多项临床试验在全球开展。

和黄医药是一家致力于创新药物研发的生物医药公司，专注于发现和开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。 自主研发的抗肿瘤新药呋喹替尼已于2018年9月获国家药品监督管理局批准上市，并于2019年11月获纳入国家医保药品目录。公司的其他候选药物，如索凡替尼、沃利替尼等，也已进入后期开发，有望在2020及2021年上市。